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Introduction
Melanoma is the deadliest form of skin cancer. An ability to detect melanoma early and
rapidly could enable effective melanoma screening and improve prognosis. S100B is an
intra-tumoural biomarker used in histopathological diagnosis of melanoma. Its serum
concentration has been associated with melanoma progression and prognosis [1]. Here,
we have validated an immunodiagnostic microneedle device for detecting S100B, with a
view to developing a diagnostic tool for early and rapid melanoma detection.
Materials and methods
The device is based on an adapted sandwich enzyme-linked immunosorbent assay (ELISA).
Microfabricated polylactic acid microneedles were surface-functionalised with an anti-
human S100B capture antibody (clone: 8B10). The microneedles were immersed in
100µg/mL recombinant human S100B or inserted into a 3-dimensional melanoma
(A375) culture for 1–3 h. Captured S100B was detected with a peroxidase-labelled,
anti-human S100B detection antibody (clone: 6G1). The chromogenic substrate was
o-phenylenediamine. Colour signals were blotted on chromatography paper for visual-
isation [2]. Since the culture medium contained 15%v/v foetal bovine serum (FBS), to
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Figure 1: ELISA result showing relationship between signal strength (mean ± standard deviation,
n = 5 independent experiments) and sample dilution factor, as a surrogate measure
of S100B concentration. Signal strength = (A − Amin)/(Amax − Amin), where A is
the absorbance of a given sample, Amax and Amin are the maximum and minimum
absorbance observed in the same experiment, respectively. Error bars are staggered
for clarity.
preclude cross-reactivity with FBS components (particularly bovine S100B), sequence
homology between human and bovine S100B was analysed using the BLASTp tool (v2.8.1;
https://blast.ncbi.nlm.nih.gov). Plate-based ELISA was performed on serially diluted
culture medium containing 4–500 ng/mL recombinant human S100B, using the same
ELISA reagents as the microneedle device. Results were compared with culture medium
minus FBS or S100B.
Results and discussion
The microneedle device detected S100B in the recombinant human S100B solution and
A375 culture. BLASTp analysis showed that human and bovine S100B proteins were 97%
identical. Plate-based ELISA showed an inverse relationship between sample dilution
factor and signal strength in all samples containing human S100B, whereas those with
FBS minus human S100B flatlined at background levels (Figure 1). Thus, there was
no evidence of cross-reactivity between the microneedle device and FBS, confirming the
cellular origin of the S100B detected in culture.
Conclusion
The immunodiagnostic device can detect human S100B in a 3-dimensional culture of
human melanoma cells in vitro. The device has potential diagnostic applications in
2
melanoma detection.
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